Join the Oncology Voice Network. Join for Free
Digital Therapeutics: Everything You Need to Know
Digital Therapeutics Medical Science Liaison COVID-19 technology adaptation opportunities in tech for MSLs future of Digital Therapeutics

Digital Therapeutics: Everything You Need to Know


Share This Article


Summary

In this episode, Tom Caravela welcomes Madleine Makori to discuss her career journey and passion for the MSL role, with a particular focus on digital therapeutics. Madleine shares insights into the differentiation and challenges of digital therapeutics and how COVID-19 has accelerated technology adaptation for patient populations. The conversation delves into the growing collaborations in digital therapeutics and the increasing provider interest in this field. Madleine highlights expanding opportunities for MSLs in tech and the importance of education in this evolving area. The episode concludes with an invitation for audience engagement and a call to subscribe.

Madleine Makori, Sr Medical Science Liaison at Big Health discusses everything you need to know about Digital Therapeutics

Maddy explains…

πŸ‘‰ What is Digital Therapeutics and how it differs from wellness and lifestyle apps

πŸ‘‰ How Digital Therapeutics is making an impact on the pharmaceutical industry

πŸ‘‰ The impact of Covid-19 and the development of the space

πŸ‘‰ What opportunities may emerge and what it means for Medical Affairs

πŸ‘‰ What the future looks like for the Digital Therapeutics space and what people need to know

Click for Source
Digital Therapeutics, Medical Science Liaison, COVID-19 technology adaptation, opportunities in tech for MSLs, future of Digital Therapeutics

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Explore OVN